Eton Pharmaceuticals, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Eton Pharmaceuticals, Inc. (ETON), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are ETON insiders buying or selling?
In the last 12 months, Eton Pharmaceuticals, Inc. insiders reported 0 open-market purchases ($0) and 11 sales ($29.4M) — net selling of $29.4M. Since November 2018, Trabud has recorded 42 Form 4 filings for ETON: 18 buys ($4.4M) and 24 sells ($55.8M).
Source: SEC EDGAR Form 4
What stands out
- No Eton Pharmaceuticals, Inc. insider made an open-market purchase in the last 12 months; the 11 reported open-market sales totaled $29.4M.
Key Statistics (November 2018 – Oct 6, 2026)
Total Form 4 filings
42
SEC EDGAR
Insider filers
11
Insider buys (18)
$4.4M
Insider sells (24)
$55.8M
Insider sentiment
Net sellingNet insider flow of $51.4M in net selling since November 2018, and $29.4M in net selling over the last 12 months.
Recent ETON insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 6, 2026 | David Krempa | Chief Business Officer | Sale | 4.2K | $55.07 | $229.4K | SEC ↗ |
| Aug 31, 2026 | Paul V Maier | Director | Sale | 50.0K | $59.07 | $3.0M | SEC ↗ |
| Aug 28, 2026 | Paul V Maier | Director | Sale | 50.0K | $59.07 | $3.0M | SEC ↗ |
| Aug 24, 2026 | David Krempa | Chief Business Officer | Sale | 25.0K | $65.07 | $1.6M | SEC ↗ |
| Aug 20, 2026 | Sean Brynjelsen | President & CEO | Sale | 100.0K | $60.88 | $6.1M | SEC ↗ |
| Jul 17, 2026 | Opaleye Management Inc. | 10% Owner | Sale | 28.3K | $37.54 | $1.1M | SEC ↗ |
| Jul 16, 2026 | Opaleye Management Inc. | 10% Owner | Sale | 28.3K | $37.54 | $1.1M | SEC ↗ |
| Jul 7, 2026 | Opaleye Management Inc. | 10% Owner | Sale | 126.7K | $37.64 | $4.8M | SEC ↗ |
| Jun 17, 2026 | Jennifer Mckie Adams | Director | Sale | 50.0K | $32.48 | $1.6M | SEC ↗ |
| May 29, 2026 | Sean Brynjelsen | President & CEO | Sale | 120.0K | $31.88 | $3.8M | SEC ↗ |
| May 27, 2026 | David Krempa | Chief Business Officer | Sale | 100.0K | $32.30 | $3.2M | SEC ↗ |
| Aug 20, 2025 | James R. Gruber | Chief Financial Officer | Sale | 41.7K | $16.15 | $673.7K | SEC ↗ |
| Jun 16, 2025 | David Krempa | Chief Business Officer | Sale | 34.0K | $14.83 | $504.3K | SEC ↗ |
| Jun 12, 2025 | Opaleye Management Inc. | 10% Owner | Purchase | 7.9K | $15.82 | $125.5K | SEC ↗ |
| Jun 5, 2025 | Sean Brynjelsen | President & CEO | Sale | 210.0K | $17.11 | $3.6M | SEC ↗ |
| Oct 25, 2024 | Opaleye Management Inc. | 10% Owner | Purchase | 10.0K | $7.98 | $79.8K | SEC ↗ |
| Oct 8, 2024 | Opaleye Management Inc. | 10% Owner | Purchase | 62.1K | $6.99 | $434.1K | SEC ↗ |
| Sep 12, 2024 | Opaleye Management Inc. | 10% Owner | Purchase | 107.5K | $4.70 | $504.9K | SEC ↗ |
| Sep 23, 2022 | Sean Brynjelsen | Chief Executive Officer | Purchase | 10.0K | $2.10 | $21.0K | SEC ↗ |
| Nov 19, 2021 | Opaleye Management Inc. | 10% Owner | Sale | 25.0K | $4.67 | $116.7K | SEC ↗ |
| Nov 17, 2021 | Opaleye Management Inc. | 10% Owner | Sale | 15.4K | $4.85 | $74.9K | SEC ↗ |
| Nov 9, 2021 | Opaleye Management Inc. | 10% Owner | Sale | 220.4K | $6.25 | $1.4M | SEC ↗ |
| Nov 5, 2021 | Opaleye Management Inc. | 10% Owner | Sale | 202.2K | $6.49 | $1.3M | SEC ↗ |
| Oct 13, 2021 | Opaleye Management Inc. | 10% Owner | Sale | 165.1K | $5.03 | $830.7K | SEC ↗ |
| Aug 20, 2021 | William Wilson Troutman | CFO, Treasurer & Secretary | Purchase | 5.0K | $4.43 | $22.1K | SEC ↗ |
Showing the 25 most recent of 42 Form 4 filings for Eton Pharmaceuticals, Inc..
Most active ETON insiders
- Opaleye Management Inc.17 filings
- Sean Brynjelsen9 filings
- David Krempa4 filings
- Paul V Maier3 filings
- Charles J Casamento2 filings
Ask anything about ETON insider activity
Use Trabud's AI agent to query Eton Pharmaceuticals, Inc.'s Form 4 history in plain English — "Show me ETON CEO purchases this year" or compare it against any other ticker.
Open the AI agentETON insider trading FAQ
Are Eton Pharmaceuticals, Inc. insiders buying or selling?
In the last 12 months, Eton Pharmaceuticals, Inc. insiders reported 0 open-market purchases ($0) and 11 sales ($29.4M) — net selling of $29.4M. Since November 2018, Trabud has recorded 42 Form 4 filings for ETON: 18 buys ($4.4M) and 24 sells ($55.8M). Over the full record that is net selling of $51.4M.
How many insiders trade ETON stock?
11 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Eton Pharmaceuticals, Inc.. The most recent filing was accepted on Oct 6, 2026.
Where does Trabud get ETON insider trading data?
All ETON insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.